vs

Side-by-side financial comparison of Caledonia Mining Corp Plc (CMCL) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $46.9M, roughly 1.6× Caledonia Mining Corp Plc). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 13.8%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 17.1%).

Hochschild Mining plc is a leading British-based silver and gold mining business operating in North, Central, and South America. It is headquartered in Lima, Peru, with a corporate office in London, is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The main shareholder is the Peruvian businessman Eduardo Hochschild.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CMCL vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.6× larger
PBYI
$75.5M
$46.9M
CMCL
Growing faster (revenue YoY)
PBYI
PBYI
+13.9% gap
PBYI
27.7%
13.8%
CMCL
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
17.1%
CMCL

Income Statement — Q3 FY2024 vs Q4 FY2025

Metric
CMCL
CMCL
PBYI
PBYI
Revenue
$46.9M
$75.5M
Net Profit
$3.3M
Gross Margin
41.2%
69.3%
Operating Margin
18.6%
22.7%
Net Margin
7.0%
Revenue YoY
13.8%
27.7%
Net Profit YoY
-33.3%
EPS (diluted)
$0.13
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMCL
CMCL
PBYI
PBYI
Q4 25
$75.5M
Q3 25
$54.5M
Q2 25
$52.4M
Q1 25
$46.0M
Q4 24
$59.1M
Q3 24
$46.9M
$80.5M
Q2 24
$50.1M
$47.1M
Q1 24
$38.5M
$43.8M
Net Profit
CMCL
CMCL
PBYI
PBYI
Q4 25
Q3 25
$8.8M
Q2 25
$5.9M
Q1 25
$3.0M
Q4 24
Q3 24
$3.3M
$20.3M
Q2 24
$10.2M
$-4.5M
Q1 24
$2.1M
$-4.8M
Gross Margin
CMCL
CMCL
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
41.2%
63.9%
Q2 24
45.8%
77.4%
Q1 24
35.9%
75.5%
Operating Margin
CMCL
CMCL
PBYI
PBYI
Q4 25
22.7%
Q3 25
17.6%
Q2 25
12.7%
Q1 25
8.7%
Q4 24
22.6%
Q3 24
18.6%
27.4%
Q2 24
32.2%
-4.6%
Q1 24
13.8%
-5.3%
Net Margin
CMCL
CMCL
PBYI
PBYI
Q4 25
Q3 25
16.2%
Q2 25
11.2%
Q1 25
6.5%
Q4 24
Q3 24
7.0%
25.2%
Q2 24
20.3%
-9.6%
Q1 24
5.4%
-11.0%
EPS (diluted)
CMCL
CMCL
PBYI
PBYI
Q4 25
$0.26
Q3 25
$0.17
Q2 25
$0.12
Q1 25
$0.06
Q4 24
$0.40
Q3 24
$0.13
$0.41
Q2 24
$0.42
$-0.09
Q1 24
$0.07
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMCL
CMCL
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$7.2M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$231.0M
$130.3M
Total Assets
$339.7M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMCL
CMCL
PBYI
PBYI
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$7.2M
$96.7M
Q2 24
$15.4M
$96.8M
Q1 24
$1.8M
$107.2M
Total Debt
CMCL
CMCL
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
CMCL
CMCL
PBYI
PBYI
Q4 25
$130.3M
Q3 25
$115.3M
Q2 25
$104.7M
Q1 25
$97.1M
Q4 24
$92.1M
Q3 24
$231.0M
$71.1M
Q2 24
$231.1M
$48.5M
Q1 24
$220.3M
$51.0M
Total Assets
CMCL
CMCL
PBYI
PBYI
Q4 25
$216.3M
Q3 25
$202.9M
Q2 25
$194.9M
Q1 25
$196.2M
Q4 24
$213.3M
Q3 24
$339.7M
$220.7M
Q2 24
$338.5M
$205.0M
Q1 24
$321.8M
$214.1M
Debt / Equity
CMCL
CMCL
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMCL
CMCL
PBYI
PBYI
Operating Cash FlowLast quarter
$4.6M
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.40×
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMCL
CMCL
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$4.6M
$11.0M
Q2 24
$19.1M
$1.0M
Q1 24
$11.2M
Free Cash Flow
CMCL
CMCL
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
CMCL
CMCL
PBYI
PBYI
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
Q3 24
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
CMCL
CMCL
PBYI
PBYI
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CMCL
CMCL
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.21×
Q4 24
Q3 24
1.40×
0.54×
Q2 24
1.87×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons